Lupin has strengthened its presence in the high-value U.S. pharmaceutical market with the launch of its long-acting injectable (LAI) generic formulation of Risperidone. The product, an extended-release injectable suspension, has been introduced in three dosage strengths – 25 mg, 37.5 mg, and 50 mg, mirroring the innovator’s profile and offering prescribers a therapeutically equivalent alternative. This launch is important not only from a generic competition standpoint but also because Lupin has secured 180-day Competitive Generic Therapy (CGT) exclusivity, giving it a significant commercial advantage during the initial months of market entry.
This Risperidone LAI is the first product developed through Lupin’s proprietary long-acting injectable platform, which the company refers to as PrecisionSphere™ technology. The formulation was created by Nanomi B.V., Lupin’s Netherlands-based subsidiary specializing in complex drug delivery systems. The successful commercialization of this platform signals Lupin’s transition from a largely oral-solids-focused generic player to a more diversified pharmaceutical company capable of producing complex and high-margin therapies.
The product is approved for the treatment of schizophrenia in adults, one of the largest therapeutic areas within psychiatry. It is also cleared for use as monotherapy or adjunctive therapy in adults with bipolar I disorder. These indications have seen rising global demand for long-acting depot antipsychotics, as such products help improve medication adherence, reduce relapse risk, and provide more stable therapeutic outcomes. For patients and caregivers, injectable formulations that last for extended periods can significantly reduce the burden of daily medication.
The reference listed drug (RLD), Risperdal Consta®, generates approximately USD 187 million in annual U.S. sales, according to IQVIA MAT September 2025 data cited in the report. This established market size provides Lupin with a meaningful revenue opportunity, especially under the CGT exclusivity period, which grants limited competition and allows early entrants to build strong institutional relationships with healthcare providers, clinics, and long-term psychiatric care facilities.
Lupin’s entry into the LAI space comes at a strategically important time. The U.S. healthcare system is increasingly adopting long-acting injectables for psychiatric conditions due to their clinical advantages and reduced risk of non-adherence. Within this context, Lupin’s technology platform positions the company well for future launches. PrecisionSphere™ technology uses advanced microsphere-based delivery designed to ensure consistent drug release over extended periods. This makes it suitable for additional therapies where long-acting profiles improve patient outcomes.
Commercially, the launch is expected to enhance Lupin’s U.S. portfolio mix, which has been seeing steady momentum in complex generics and specialty products. The company has been prioritizing high-barrier-to-entry products as part of its growth strategy, especially in markets where competition is limited and pricing is stable. The CGT exclusivity further amplifies the financial attractiveness of the launch by preventing other generic competitors from entering for six months, unless they also receive CGT approval.
From a strategic perspective, Lupin’s move into the LAI category can be seen as a long-term value driver. The psychiatric LAI market in the U.S. continues to expand as newer formulations demonstrate better clinical outcomes. By establishing a strong presence early through a complex-to-manufacture product like Risperidone LAI, the company is laying the groundwork for a pipeline of future long-acting therapies targeting neurology, psychiatry, and chronic disease management.
Overall, this launch marks a major milestone for Lupin as it begins commercializing products from its proprietary delivery systems, expands its growth pathway in the U.S., and successfully enters a technically challenging and high-margin therapy area.